Clinical Trials

160 enrolled

Urinary Bladder Neoplasms

NCT06235697 2026-04-14

ASCENDE-SBRT

710 enrolled

Prostatic Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT05050084 2026-04-08

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

2,050 enrolled

Prostate Adenocarcinoma

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT04423211 2026-04-03

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

804 enrolled

Prostatic Neoplasms

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT05946213 2026-04-03

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

1,209 enrolled

Prostatic Neoplasms

NCT06244004 2026-03-30

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

125 enrolled

Prostatic Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT06171269 2026-03-04

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Phase NA Recruiting

60 enrolled

Prostatic Neoplasms

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

256 enrolled

Wilms Tumor

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

72 enrolled

Prostatic Neoplasms

NCT06037863 2026-02-23

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

168 enrolled

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT03861676 2026-02-13

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

20 enrolled

Prostatic Neoplasms

NCT06625034 2026-02-10

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

108 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

125 enrolled

BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT07202247 2026-02-04

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

60 enrolled

Prostatic Neoplasms

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

118 enrolled

Prostatic Neoplasms

NCT03070886 2026-01-14

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

612 enrolled

Phase 2 Active not recruiting

Stage I Prostate Adenocarcinoma AJCC v7

NCT03371719 2026-01-14

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

324 enrolled

Prostatic Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

586 enrolled

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

100 enrolled

Phase 1 Active not recruiting

Prostate Adenocarcinoma

NCT06105918 2025-12-09

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

6 enrolled

Phase 1 Active not recruiting

Biochemically Recurrent Prostate Carcinoma

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT05805371 2025-11-19

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

21 enrolled

Prostatic Neoplasms

NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

110 enrolled

Oligometastatic Prostate Carcinoma

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

186 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

95 enrolled

Urinary Bladder Neoplasms

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT01495676 2025-10-10

GETUGV04

Phase NA Terminated

69 enrolled 9 charts

Urinary Bladder Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03889119 2025-09-15

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT05230251 2025-09-12

ROADSTER

Phase 1/2 Completed

3 enrolled

Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

1,273 enrolled

GastrointestinalGenitourinaryGynecologic

Prostatic Neoplasms

NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

Phase 2 Completed

43 enrolled 13 charts

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT01492972 2025-09-04

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

192 enrolled

Prostatic Neoplasms

NCT03570827 2025-09-03

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Phase 2 Completed

52 enrolled

Prostatic Neoplasms

NCT01508390 2025-06-26

Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

35 enrolled

Prostatic Neoplasms

NCT04249154 2025-06-25

PROMPT

77 enrolled

Prostatic Neoplasms

NCT01342367 2025-06-10

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

74 enrolled 12 charts

Prostatic Neoplasms

NCT00945009 2025-05-31

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

249 enrolled 14 charts

DermatologicGenitourinaryHead & NeckThoracic

Beckwith-Wiedemann Syndrome, Wilms Tumor

NCT02318771 2025-05-15

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase 1 Completed

41 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT03304418 2025-04-30

RROPE

Phase 2 Completed

20 enrolled 14 charts

Prostate Cancer Metastatic to Bone

NCT03486197 2024-11-20

Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

Phase 2 Terminated

12 enrolled 10 charts